Immuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer Immuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer

Immuneering Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104; Plans to Expand Trial with Additional Arms Immuneering Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104

Methyl Ethyl Ketone Market Evolving Trends and Leading Competitive Landscape New York, May 02, 2023 (GLOBE NEWSWIRE) -- According to a recent report by Reports Insights, the methyl ethyl ketone market is poised for strong expansion and is expected to reach USD 14.80 Billion...

MolecularMD Corp. Obtains Exclusive License to LKB1 Uses in Non-Small Cell Lung Cancer PORTLAND, OR--(Marketwire - Jan 28, 2013) - MolecularMD Corp. announced today that it has entered into a license agreement granting the company exclusive patent rights to cancer diagnosis...